WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) today announced that it has commenced its offer to exchange up to $67,710,000 aggregate principal amount of new 12.50% Convertible Senior Notes due 2011 and shares of the Company’s common stock for up to all of the $225,700,000 aggregate principal amount of its currently outstanding 3.50% Convertible Senior Notes due 2011.
